Advertisement

First-Line Therapy and Special Issues Management in Polycythemia Vera and Essential Thrombocythemia

  • Tiziano Barbui
Chapter
Part of the Hematologic Malignancies book series (HEMATOLOGIC)

Abstract

Recommendations for management of polycythemia vera (PV) and essential thrombocythemia (ET) are based on a limited number of randomized clinical and on several observational studies describing the clinical course of the diseases and indirectly evaluating the role of different treatments. According to European LeukemiaNet (ELN) recommendations published in 2011, first-line therapy in all patients with PV should be phlebotomy to maintain the hematocrit less than 45% and low-dose aspirin (75–100 mg). Cytoreduction is strongly indicated in high-risk cases defined by age and previous major vascular events. In patients with PV, initially defined at low risk, poor tolerance to or high need of phlebotomy, symptomatic or progressive splenomegaly, severe disease-related symptoms, platelet counts greater than 1.5 × 109/L, or progressive leukocytosis are indications for cytoreductive therapy. Either hydroxyurea or interferon alpha is the first-line therapy at any age. Intermittent busulfan may be considered in elderly patients. No cytoreductive drugs in otherwise low-risk patients carrying well-controlled cardiovascular risk factors is recommended. All patients with ET presenting microvascular disturbances should be managed with low-dose aspirin (75–100 mg). Cytoreduction with HU is the first-line therapy in high-risk patients at any age. The use of cytoreductive drugs in otherwise low-risk patients carrying well-controlled cardiovascular risk factors is not generally indicated.

Keywords

Polycythemia Vera Essential Thrombocythemia JAK2 V617F Polycythemia Vera Patient Cytoreductive Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Alvarez-Larran A, Cervantes F, Pereira A et al (2010) Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 116:1205–1210PubMedCrossRefGoogle Scholar
  2. Antonioli E, Guglielmelli P, Pieri L et al (2011) Side effects of hydroxyurea in classic chronic myeloproliferative neoplasms. A retrospective study of 3,411 patients. 16th Congress EHA, London (abstract)Google Scholar
  3. Barbui T, Finazzi G (2005) When and how to treat essential thrombocythemia. N Engl J Med 353:85–86PubMedCrossRefGoogle Scholar
  4. Barbui T, Barosi G, Grossi A et al (2004) Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 89:215–232PubMedGoogle Scholar
  5. Barbui T, Thiele J, Passamonti F et al (2011a) Survival and risk of leukemic transformation in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study on 1,104 patients. J Clin Oncol 29:3179–3184PubMedCrossRefGoogle Scholar
  6. Barbui T, Barosi G, Birgegard G et al (2011b) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29:761–770PubMedCrossRefGoogle Scholar
  7. Belay ED, Bresee JS, Holman RC et al (1997) Reye’s syndrome in the United States from 1981 through 1997. N Engl J Med 340:1377–1382CrossRefGoogle Scholar
  8. Berk PD, Goldberg JD, Donovan PB et al (1986) Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 23:132–143PubMedGoogle Scholar
  9. Bjorkholm M, Derolf AR, Hultcranz M et al (2011) Treatment related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. doi: 10.1200/JCO.2011.34.7542
  10. Campbell PJ, Scott LM, Buck G et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366:1945–1953PubMedCrossRefGoogle Scholar
  11. Campbell PJ, Bareford D, Erber WN et al (2009) Reticulin accumulation in essential thrombocythemia: prognostic significance and relation to therapy. J Clin Oncol 27:2991–2999PubMedCrossRefGoogle Scholar
  12. Cervera JS, Mena-Duran AV, Piqueras CS (2005) The use of recombinant factor VIIa in a patient with essential thrombocythemia with uncontrolled surgical bleeding. Thromb Haemost 93:383–384PubMedGoogle Scholar
  13. Chait Y, Condat B, Cazals-Hatem D et al (2005) Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 129:553–560PubMedCrossRefGoogle Scholar
  14. Chung RT, Iafrate AJ, Amrein PC et al (2006) Case 15–2006: a 46-year-old woman with sudden onset of abdominal distention. N Engl J Med 354:2166–2175PubMedCrossRefGoogle Scholar
  15. Condat B, Pessione F, Hillaire S et al (2001) Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 120:490–497PubMedCrossRefGoogle Scholar
  16. Cortelazzo S, Finazzi G, Ruggeri M et al (1995) Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: a prospective randomized trial. N Engl J Med 332:1132–1136PubMedCrossRefGoogle Scholar
  17. Dame C, Sutor AH (2005) Primary and secondary thrombocytosis in childhood. Br J Haematol 129:165–177PubMedCrossRefGoogle Scholar
  18. Di Nisio M, Barbui T, Gennaro D et al (2007) The hematocrit and platelet target in polycythemia vera. Br J Haematol 136:249–259PubMedCrossRefGoogle Scholar
  19. Elliott MA, Tefferi A (2003) Thrombocythaemia and pregnancy. Best Pract Res Clin Hematol 16:227–242CrossRefGoogle Scholar
  20. Finazzi G, Ruggeri M, Rodeghiero F et al (2000) Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 110:577–583PubMedCrossRefGoogle Scholar
  21. Finazzi G, Ruggeri M, Rodeghiero F et al (2003) Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood 101:3749PubMedCrossRefGoogle Scholar
  22. Finazzi G, Caruso V, Marchioli R et al (2005) Acute leukemia in polycythemia vera. An analysis of 1,638 patients enrolled in a prospective observational study. Blood 105:2664–2670PubMedCrossRefGoogle Scholar
  23. Fruchtman SM, Mack K, Kaplan ME et al (1997) From efficacy to safety: a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 34:17–23PubMedGoogle Scholar
  24. Gangat N, Strand J, Li CY et al (2007) Leucocytosis in polycythemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 138:354–358PubMedCrossRefGoogle Scholar
  25. Gisslinger H, Kralovics R, Gotic M et al (2007) Non-inferiority of anagrelide compared to hydroxyurea in newly diagnosed patients with essential thrombocythemia. The ANAHYDRET-Study. Blood 110:3547 (abstract)CrossRefGoogle Scholar
  26. Harrison C, Barbui T (2011) Aspirin in low-risk essential thrombocythemia, not so simple after all? Leuk Res 35:286–289PubMedCrossRefGoogle Scholar
  27. Harrison CN, Campbell PJ, Buck G et al (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353:33–45PubMedCrossRefGoogle Scholar
  28. Harrison CN, Bareford D, Butt N et al (2010) Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 149:352–375PubMedCrossRefGoogle Scholar
  29. Kiladjian JJ, Cassinat B, Turlure P et al (2006) High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 108:2037–2040PubMedCrossRefGoogle Scholar
  30. Kiladjian JJ, Chevret S, Dosquet C et al (2008a) Long-term outcome in polycythemia vera: final analysis of a randomized trial comparing hydroxyurea (HU) to pipobroman (Pi). Blood 112: abstract 1746Google Scholar
  31. Kiladjian JJ, Cassinat B, Chevret S et al (2008b) Pegylated interferon alpha-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112:3065–3072PubMedCrossRefGoogle Scholar
  32. Kiladjian JJ, Cervantes F, Leebek FWG et al (2008c) The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 111:4922–4929PubMedCrossRefGoogle Scholar
  33. LandolfiR, Marchioli R, Kutti J et al (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350:114–124PubMedCrossRefGoogle Scholar
  34. Lengfelder E, Griesshammer M, Hehlmann R (1996) Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 22(suppl 1):135–142PubMedCrossRefGoogle Scholar
  35. Martinelli I, Franchini M, Mannucci PM (2008) How I treat rare venous thrombosis. Blood 112:4818–4823PubMedCrossRefGoogle Scholar
  36. Najean Y, Rain JD for the French Polycythemia Study Group (1997) Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 90:3370–3377Google Scholar
  37. Narayanan Menon KV, Shah V, Kamath PS (2004) The Budd-Chiari syndrome. N Engl J Med 350:578–585CrossRefGoogle Scholar
  38. Patel RK, Lea N, Heneghan A et al (2006) Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 130:2031–2038PubMedCrossRefGoogle Scholar
  39. Patrono C, Baigent C, Hirsh J et al (2008) Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133:234S–256SCrossRefGoogle Scholar
  40. Pearson TC, Wetherley-Mein G (1978) Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 2:1219–1222PubMedCrossRefGoogle Scholar
  41. Pieri L, Bogani C, Guglielmelli P et al (2009) The JAK2V617F mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica 94:1484–1488CrossRefGoogle Scholar
  42. Quintas-Cardama A, Kantarjian H, Manshouri T et al (2009) Pegylated interferon alpha-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27:5418–5424PubMedCrossRefGoogle Scholar
  43. Ruggeri M, Rodeghiero F, Tosetto A et al (2008) Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood 111:666–671PubMedCrossRefGoogle Scholar
  44. Saini KS, Patnaik MM, Tefferi A (2010) Polycythemia vera-associated pruritus and its management. Eur J Clin Invest 40:828–834PubMedCrossRefGoogle Scholar
  45. Samuelsson J, Mutschler M, Birgegard G et al (2006) Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica 91:1281–1282PubMedGoogle Scholar
  46. Silver RT (2006) Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 107:451–458PubMedCrossRefGoogle Scholar
  47. Silver RT, Vandris K, Goldman JJ et al (2009) Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. Blood 114:1908 (abstract)Google Scholar
  48. Spivak J (2004) Daily aspirin. Only half the answer. N Engl J Med 350:99–101PubMedCrossRefGoogle Scholar
  49. Sterkers Y, Preudhomme C, Lai J-L et al (1998) Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 91:616–622PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Research Foundation Ospedale Maggiore (FROM) and Hematology DepartmentOspedali RiunitiBergamoItaly

Personalised recommendations